in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
AMRI completes acquisition of API firm Cedarburg
7:58 AM MDT | April 7, 2014 | Deepti Ramesh
Albany Molecular Research Inc. (AMRI; Albany, NY) says that it has completed the previously announced acquisition of Cedarburg Hauser Pharmaceuticals (Grafton, WI). Total consideration that's been paid is $41 million, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. Cedarburg is a contract developer and manufacturer of technically complex active pharmaceutical ingredients (APIs) for both generic and branded customers. Cedarburg's revenue forecast for full-year 2014 is about $19 million, AMRI says. The acquisition is...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee